GKOS (Glaukos) Cash per Share: $4.74 (As of Mar. 2026)

What is Glaukos Cash per Share?

Glaukos GKOS -1.52% 80 Cash per Share is $4.74 as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $136.41 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Glaukos's Cash per Share for the quarter that ended in Mar. 2026 was $4.74.

Glaukos (NYSE:GKOS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Glaukos Cash per Share Related Terms

Glaukos Cash per Share Historical Data

* Premium members only.

The historical data trend for Glaukos's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Cash per Share Chart

Glaukos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

8.82

7.39

6.01

5.65

4.85

Glaukos Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															5.26	4.80	4.77	4.85	4.74

80GF Score

Glaukos Corp GKOS

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Glaukos Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Glaukos's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	278.76	/	57.5
	=	4.85

Glaukos's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	276.685	/	58.4
	=	4.74

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $4.74 mean?

Glaukos (GKOS) has a Cash per Share of $4.74 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Glaukos and its competitors.

Is Glaukos' Cash per Share too high?

Glaukos' current Cash per Share is $4.74. Overall, Glaukos has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Glaukos' Cash per Share compare to BIO and BRKR?

Glaukos' Cash per Share of $4.74 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Medical Devices & Instruments company?

A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Glaukos and its competitors. Glaukos's current Cash per Share is $4.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Glaukos stock overvalued right now?

Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.41, compared to a current price of $152.72 — trading 12% above its estimated fair value. The current Cash per Share is $4.74. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Glaukos (GKOS), the current Cash per Share is $4.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $152.72 is trading 12% above its estimated GF Value™ of $136.41. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for GKOS:

Cash per Share: $4.74
GF Value™: $136.41 vs. price of $152.72 (12% above fair value)
GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies BIO BRKR PODD GMED LIVN PEN IRTC HAE ITGR ESTA ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges 6GJ:Germany

Address One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

80GF Score

Get the complete analysis for GKOS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$152.72

Price

$136.41

GF Value

View GKOS Analysis

See Cash per Share data for all stocks →